Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026)

Denali Therapeutics has reported Long-Term Investments over the past 9 years, most recently at $98.3 million for Q4 2025.

  • Quarterly Long-Term Investments fell 72.64% to $98.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.3 million through Dec 2025, down 72.64% year-over-year, with the annual reading at $98.3 million for FY2025, 72.64% down from the prior year.
  • Long-Term Investments was $98.3 million for Q4 2025 at Denali Therapeutics, up from $24.7 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $490.7 million in Q1 2024 and troughed at $7.9 million in Q3 2023.
  • The 5-year median for Long-Term Investments is $235.8 million (2025), against an average of $227.5 million.
  • Year-over-year, Long-Term Investments skyrocketed 5535.21% in 2024 and then crashed 94.45% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $425.4 million in 2021, then tumbled by 77.85% to $94.2 million in 2022, then tumbled by 91.61% to $7.9 million in 2023, then soared by 4446.15% to $359.4 million in 2024, then crashed by 72.64% to $98.3 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Long-Term Investments are $98.3 million (Q4 2025), $24.7 million (Q3 2025), and $78.5 million (Q2 2025).